JNJ-101556143 for Advanced Prostate Cancer That No Longer Responds to Hormone Therapy
Tests JNJ-101556143 in adults whose spread prostate cancer has stopped responding to hormone therapy.
Key facts
- Who runs it
- Janssen Research & Development, LLC
- Where
- Carmel, Chicago Ridge, Germantown, Lafayette, Largo, Plymouth, and Syracuse, United StatesSee the 7 sitesAlso in 3 other countries, 7 sites
- Trial code
- Registry title
- A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 16 Sept 2026
- Expected to end
- 20 May 2030
- Type of study
- Interventional
- Treatments tested
- JNJ-101556143
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that has spread and has stopped responding to hormone therapy.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Prostate cancer (adenocarcinoma) that has spread and is getting worse despite hormone therapy (mAPMR), with PSA of 10 ng/mL or higher and rising PSA or new or growing tumours on scans. Small cell, neuroendocrine and sarcoma types of prostate cancer cannot join.
- Earlier treatment
- Must be on continuing hormone-lowering treatment (ADT) or have had both testicles removed, with testosterone below 50 ng/dL. Must have stopped other cancer treatments: 2 weeks for chemotherapy, ARPI or radiation, 6 weeks for 177Lu PSMA-617, and 3 months for investigational drugs. Side effects of earlier treatment must have eased to Grade 1 or better.
- Biomarker or test result
- PSA of 10 ng/mL or higher. In Part 1, tumours that can be measured on scans (CT or MRI) and/or bone scan.
Main reasons for not taking part
- Uncontrolled kidney disease, pancreatitis or liver disease (some exceptions)
- Known allergy to JNJ-101556143 or its ingredients
- Major surgery or serious injury within 28 days before the first dose
- Spinal cord compression, unless treated and stable for 28 days
- Solid organ or bone marrow transplant
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Have histologically confirmed adenocarcinoma of the prostate. Primary (or pathologic evidence of conversion to) small cell carcinoma, carcinoid tumor, mixed neuroendocrine carcinoma, large cell neuroendocrine carcinoma, or sarcoma of the prostate is disallowed
- Progressive metastatic androgen pathway modulation-resistant prostate cancer (mAPMR) defined as having a Prostate-Specific Antigen (PSA) level greater than or equal (>=) 10 nanograms per milliliter (ng/mL) and at least one of the following: (a) PSA progression defined as at least 2 consecutive increases in PSA value over a previous reference value measured at least 1 week apart. (b) Progressive disease or new lesion(s) in the lymph nodes, bones, or viscera on conventional imaging (computed tomography [CT]/magnetic resonance imaging [MRI]) as defined by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) and/or on bone scan per Prostate Cancer Working Group 4 (PCWG4) while on Androgen Deprivation Therapy (ADT) (either surgically [bilateral orchiectomy] or with medication). Local-regional disease including invasive disease of rectum, bladder, pelvis is allowed as long as participant has a current or past history of distant metastasis (M1 disease). Participants in Part 1 must have measurable disease per RECIST v1.1 by conventional imaging with CT or MRI (chest, abdomen, and pelvis) and/or Technetium-99\^m (99\^mTc) bone scan confirmed by Blinded Independent Central Review (BICR) at the time of screening
- Prior bilateral orchiectomy or medical castration (receiving ongoing ADT with a Gonadotropin-Releasing Hormone (GnRH) analog [agonist or antagonist]) with castrate level of serum testosterone (less than [<] 50 nanograms per deciliter [ng/dL] or 1.7 nanomoles per liter [nmol/L]) prior to the first dose of trial intervention and must continue this therapy throughout the treatment phase
- Have discontinued concurrent use of any non-investigational systemic anticancer therapy (that is, cytotoxic chemotherapy, Androgen Receptor Pathway Inhibitor (ARPI), radiation therapy) within 2 weeks or Lutetium-177 Prostate-Specific Membrane Antigen-617 (177\^Lu PSMA-617) within 6 weeks prior to first dose of trial intervention, or any investigational drugs within 3 months of first dose of trial intervention
- Toxicity related to prior anticancer treatment that is deemed clinically relevant must have resolved to common terminology criteria for adverse events (CTCAE) Version 6.0 Grade 1 or better
Who cannot take part
- Had major surgery or had significant traumatic injury less than or equal to 28 days of the first dose of trial intervention. Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate
- Spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days
- Solid organ or bone marrow transplantation
- Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of patients with Gilbert's Syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease per investigator assessment)
- Suspected or known allergies, hypersensitivity, or intolerance to JNJ-101556143 or its excipients
Where in United States
Also in 3 other countries, 7 sites
- Urology of IndianaCarmel, United StatesTaking people
- Associated Urological SpecialistsChicago Ridge, United StatesTaking people
- The Conrad Pearson ClinicGermantown, United StatesTaking people
- Southern Urology LLCLafayette, United StatesTaking people
- Advanced Urology InstituteLargo, United StatesTaking people
- Greater Boston UrologyPlymouth, United StatesTaking people
- Associated Medical ProfessionalsSyracuse, United StatesTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate how well JNJ-101556143 works in participants with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced form of prostate cancer that has spread and no longer responds to hormone therapy. The study will measure the overall response (tumor shrinkage or disappearance) following treatment with JNJ-101556143.
The group in the trial
- JNJ-101556143Treatment being tested
Participants will receive JNJ-101556143 orally once daily in a 28-day treatment cycle until confirmed radiographic progression by blinded independent central review (BICR) or unequivocal clinical progression, or any other protocol-defined discontinuation criteria is met.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2, Open-label, Multicenter, Single-arm Trial of JNJ-101556143, an Androgen Receptor-targeted Regulated Induced Proximity Targeting Chimera (RIPTAC™) Therapeutic in Participants With Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer
- Plain-language title
- JNJ-101556143 for Advanced Prostate Cancer That No Longer Responds to Hormone TherapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 3 November 2026